OncoMatch/Clinical Trials/NCT05430399
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Is NCT05430399 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including utidelone and docetaxel for breast neoplasms.
Treatment: utidelone · docetaxel — It is a phase III trial to explore the efficacy and safety of utidelone versus docetaxel in HER2-negative locally advanced or metastatic breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative
The primary tumor and metastases (if re-biopsy was performed) were both HER2-negative
Disease stage
Required: Stage III, IV
Metastatic disease required
locally advanced or metastatic, histologically or cytologically documented breast cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: taxane — early breast cancer (neoadjuvant or adjuvant)
Previous chemotherapy with taxane for early breast cancer (eBC; neoadjuvant or adjuvant setting) is permitted if completed ≥12 months before randomization
Cannot have received: chemotherapy
Exception: adjuvant/neoadjuvant taxane completed ≥12 months before randomization
No previous chemotherapy for advanced breast cancer
Cannot have received: anti-tumor therapy
Patients who have received anti-tumor therapy within 4 weeks prior to the start of study treatment, including chemotherapy, radical radiotherapy, biological therapy, immunotherapy or anti-tumor Chinese medicine therapy
Lab requirements
Blood counts
adequate hematological function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify